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Previewswill significantly limit oocyte/embryo
manipulation, streamline the protocol,
and allow for better, more standardized
reprogramming. Additionally, isolation of
H3K9 methyltransferase inhibitors might
also help reprogramming efficiencies by
reducing the starting levels of H3K9me3
marks in somatic cells before SCNT.
Indeed, knockdown of the Suv39h1 and
Suv39h2 methyltransferases in mouse
embryonic fibroblasts globally reduced
H3K9me3 levels and improved SCNT effi-
ciencies (Matoba et al., 2014).
Finally, it is tempting to speculate that
other epigenetic modulators have the
potential of further improving reprogram-
ming efficiencies, given the fact that about642 Cell Stem Cell 17, December 3, 2015 ª2half of RRRs remain inactive even in the
presence of KDM4A (160 of 318 regions).
Moreover, a global comparison of NT-
and IVF-embryos past the eight-cell stage
might reveal other differences that pre-
vent NT-embryos from advancing to blas-
tocysts. Together, the elucidation of these
molecular pathways will not only greatly
contribute to our general understanding
of reprogramming but will also shed light
on early human development.
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Cohesin complex components are frequently mutated in human myeloid cancers. Three new studies
now show that cohesin mutations disrupt the differentiation of normal hematopoietic stem and progenitor
cells and enhance self-renewal, shedding light on how these alterations may contribute to leukemic
transformation.Genes coding for cohesin complex mem-
bers (i.e., SMC1A, SMC3, RAD21, and
STAG2) are recurrently mutated in pa-
tients with myeloid cancers such as acute
myeloid leukemia (AML), myelodysplasia,
chronic myelomonocytic leukemia, and
the transient abnormal myelopoiesis of
Down syndrome. STAG2 and RAD21 are
predominantly targeted by nonsense,
frameshift, or splice site mutations,
whereas SMC1A and SMC3 are predom-
inantly targeted by missense mutations
(Figure 1). Mutations are heterozygous,
but those targeting STAG2 and SMC1A
may be functionally homozygous given
the genes’ X chromosome location. The
presence of mutations is typically mutu-
ally exclusive between subunits. Interest-
ingly, cohesin mutations are on occasion
observed in the blood of normal aging hu-
mans without hematological malignancy,
raising the possibility that they may pro-mote a pre-leukemic stem cell state that
is predisposed toward transformation
(Kon et al., 2013; Cancer Genome Atlas
Research Network, 2013; Losada, 2014;
Jaiswal et al., 2014). Three recent reports,
one in Cell Stem Cell (Mazumdar et al.,
2015) and two in The Journal of Experi-
mental Medicine (Viny et al., 2015; Mul-
lenders et al., 2015), now describe how
such mutations may alter normal hemato-
poietic stem and progenitor cell (HSPC)
function to promote transformation.
The cohesin complex is essential in
mammalian biology. Smc3 and Rad21
null mice exhibit early embryonic lethality,
and humans with Cornelia de Lange syn-
drome (a syndrome of developmental
retardation with facial and skeletal abnor-
malities) have mutations in the cohesin
loading factor NIPBL or cohesin complex
components (Losada, 2014). Function-
ally, the complex forms a ring-like struc-ture encircling sister chromatin fibers.
During mitosis, cohesin links sister chro-
matids to facilitate proper chromosome
segregation and post-replicative DNA
repair. Outside of its roles in mitosis, co-
hesin co-occupies active promoters and
enhancers with RNA polymerase and
Mediator and promotes enhancer-pro-
moter DNA looping. It also contributes to
the topological organization of the
genome through interactions with CTCF,
stabilizes the binding of transcription fac-
tors to low-affinity DNA motifs, organizes
chromatin looping at DNA replication fac-
tories, and sustains DNA accessibility for
transcription factor binding through cell
division to provide a cellular memory of
transcriptional states (Losada, 2014).
The three new reports have explored
the outcomes of cohesin depletion or mu-
tation in the pathogenesis of myeloid ma-
lignancy. Reporting in Cell Stem Cell,
Figure 1. Cohesin Complex Mutations in Acute Myeloid Leukemia
The cartoon illustrates the structure of the cohesin complex. For each component, the percentage of AML
cases carrying mutations in its gene is indicated in brackets, together with the approximate proportion of
truncating versus missense mutations collated from five separate studies (Cancer Genome Atlas
Research Network, 2013; Kon et al., 2013; Kihara et al., 2014; Thol et al., 2014; Thota et al., 2014; n = 1,393
individuals). For ease of display, nonsense, frameshift, and splice site mutations are grouped as ‘‘trun-
cating’’ mutations, and missense and inframe indels are grouped as ‘‘missense’’ mutations.
Cell Stem Cell
PreviewsRavindra Majeti and colleagues studied
the effects of cohesin point or truncation
mutants, or RAD21 knockdown, in human
AML cell lines and primary HSPCs
(Mazumdar et al., 2015). They showed
that cohesin mutations can induce an
immunophenotypic and functional differ-
entiation block through either a domi-
nant-negative mechanism or haploinsuffi-
ciency. Given that the presence of
cohesin mutations in AML is not associ-
ated with aneuploidy, the authors next
explored whether cohesin mutants
impact some of the non-mitotic functions
of the complex. They measured chro-
matin accessibility across the genome in
primary human HSPCs expressing a trun-
cated RAD21 protein or an R711G
SMC1A mutant, using transposase-
accessible chromatin followed by
sequencing (ATAC-seq). They found
increased accessibility of ERG, GATA2,
and RUNX1 DNA binding motifs in com-
parison with control cells, despite
genome-wide reductions in overall chro-
matin accessibility at enhancers and
promoters. Critically, the cohesin-
mutant-induced block in differentiation in
primary HSPCs was dependent upon
ERG, GATA2, or RUNX1, known regula-
tors of HSPCs, as shRNA-mediatedknockdown of those factors rescued
HSPC differentiation.
In the second study, the Aifantis group
and colleagues (Mullenders et al., 2015)
used a genetic knockdown strategy to
deplete cohesin complex components in
murine bone marrow HSPCs in vitro and
in vivo. They too observed enhanced se-
rial replating of progenitors in vitro and
an expansion of parts of the immunophe-
notypic HSPC compartment, with cohe-
sin-knockdown HSPCs displaying skew-
ing toward myeloid lineage commitment.
Interestingly, knockdown of one complex
component member in vivo led to
reduced protein levels of the other com-
plex components. Also of note was that
cohesin component knockdown reliably
increased the size of the nucleus, perhaps
indicating reduced chromatin compac-
tion. The authors performed ATAC-seq
in STAG2 knockdown cells and, consis-
tent with the findings of Mazumdar et al.,
found an increased frequency of acces-
sible GATA motifs. Furthermore, recipient
mice which received cohesin knockdown
HSPCs developed a myeloproliferative
disorder as they aged, consistent with
the hypothesis that reduced cohesin
complex levels contribute to hematologic
disease.Cell Stem Cell 17,In the third study, Ross Levine and col-
leagues (Viny et al., 2015) studied mice
after they conditionally deleted Smc3 al-
leles. Consistent with cohesin’s essential
role, complete deletion of Smc3 led
to rapid bone marrow failure, with stem
cell loss and metaphase polyploidy. In
contrast, and in line with the studies dis-
cussed above, deletion of oneSmc3 allele
led to an expansion of the immunopheno-
typic HSPC compartment. This expansion
was consistent with enhanced progenitor
cell serial replating capacity in vitro and
enhanced competitiveness of HSPCs
in vivo. Crossing Smc3 mice with a strain
expressing the AML Flt3-ITD oncogene
showed that Smc3 haploinsufficiency,
while not leading to AML by itself, potently
collaborated with Flt3-ITD to induce AML.
ATAC-seq analyses revealed increased
accessibility of STAT5 binding sites, sug-
gesting that this disease mechanism may
involve enhanced STAT5 signaling.
Perhaps in contrast to the previous two
studies, fewer accessible GATA1 and
GATA2 binding sites were found in
Smc3+/ Flt3-ITD versus Smc3WT Flt3-
ITD HSPCs. Likewise, there was relatively
little change in chromatin accessibility by
ATAC-seq in Smc3+/ cells in comparison
with control cells, although transcriptome
analysis suggested a modest global
reduction in transcription. Smc3 haploin-
sufficiency was associated with an
increased number of nucleoli, again sug-
gesting that cohesin has important roles
in the organization of chromatin structure
and nuclear sub-domains.
Together these studies convincingly
indicate that depletion of cohesin com-
plex components contributes to transfor-
mation of normal HSPCs through retard-
ing or skewing differentiation and
promoting stem and/or progenitor cell
expansion. In the murine models, cohesin
depletion alone was not sufficient to
induce AML, but it was able to collaborate
with Flt3-ITD to induce full-fledged dis-
ease. Thus mutant cohesin, like other mu-
tations in myeloid malignancy, requires
cooperating genetic lesions for cellular
transformation. Importantly, the effect of
cohesin depletion is dose dependent
because complete loss leads to aneu-
ploidy and stem cell failure. What remains
a challenge is to understand fully the
mechanistic details by which cohesin mu-
tants promote transformation, given the
promiscuous and genome-wide bindingDecember 3, 2015 ª2015 Elsevier Inc. 643
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Previewsof the complex. While themutant-induced
differentiation block observed by Mazum-
dar and colleagues is dependent upon
GATA2 and other transcription factors, it
is unclear why GATA binding sites in
particular retain both accessibility and
transcription factor occupancy. One sug-
gestion is that transcription factors like
GATA2 exhibit pioneer activity (i.e., they
can directly bind condensed chromatin)
and may be less dependent on cohesin
than other transcription factors for stable
interaction with chromatin. However, an
alternative possibility may be that the
observed accessibility of GATA binding
sites is a consequence of the differentia-
tion block rather than a driver of it, and
that normal cohesin levels may be
required for the proper promoter-
enhancer interactions required for termi-
nal myeloid differentiation. It seems likely644 Cell Stem Cell 17, December 3, 2015 ª2that more remains to be learned about
the cellular mechanisms by which the
various cohesin mutants contribute to
the pathogenesis of human myeloid
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The identification of tumor-initiating cells represents a significant challenge for studies of prostate cancer. In
a recent issue of Cell Reports, Agarwal and colleagues use organoid culture to ascertain two distinct luminal
progenitors in a mouse model of prostate cancer, shedding new light on lineage relationships in the prostate
epithelium.Despite the clinical significance of pros-
tate cancer, several of the existing
experimental systems used to investigate
its properties have significant limitations.
Notably, few human prostate cancer cell
lines are available for analysis, these
lines are not representative of most
stages of the disease, and establishing
patient-derived xenografts remains
challenging.
In part, these difficulties are associated
with specific properties of epithelial cells
in the normal and transformed prostate
(reviewed in Wang and Shen, 2011). In
the normal prostate epithelium, there arethree primary cell types, corresponding to
the luminal secretory cells, the underlying
basal support cells, and rare neuroendo-
crine cells. In contrast, prostate adenocar-
cinomas,which represent the vastmajority
of prostate tumors, are composed of cells
with a luminal phenotype and are largely
devoid of basal cells. However, prostate
luminal cells are extremely sensitive to
tissue dissociation, after which they fail to
survive in explant culture or grafts, likely
explaining the difficulty in establishing cell
lines aswell as patient-derived xenografts.
As a consequence, there has been an
important gap in our understanding ofthe properties of prostate luminal epithe-
lial cells. Luminal cells have been tradi-
tionally regarded as terminally differenti-
ated and thus unlikely to possess stem/
progenitor activity. On the other hand,
the basal compartment has been consid-
ered a source of stem cells. In the
context of cancer, studies using geneti-
cally engineered mice have identified
tumor-initiating cells in a Pten mutant
model of prostate cancer (Mulholland
et al., 2009), but luminal tumor-initiating
cells have not been identified to date in
either mouse models or human primary
tumors.
